D. Rijken

发表

Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity.

L. Nelles, C. Kluft, H. K. Nieuwenhuis, 1987, Science.

Studies on lysophospholipases. 3. The complete purification of two proteins with lysophospholipase activity from beef liver.

L. van Deenen, D. Rijken, J. D. de Jong, 1974, Biochimica et biophysica acta.

The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.

J. Verheijen, A. Aasen, J. Jespersen, 1985, Scandinavian journal of clinical and laboratory investigation.

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study 1

J. Deckers, A. Gils, P. Declerck, 2009, Journal of thrombosis and haemostasis : JTH.

The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells.

J. Grimbergen, D. Rijken, A. Collen, 2000, Biochimica et biophysica acta.

Modulation of Rapid Plasminogen Activator Inhibitor in Plasma by Stanozolol

J. Verheijen, C. Kluft, F. Preston, 1984, Thrombosis and Haemostasis.

Fibrinolytic Activators and Inhibitors in Terminal Renal Insufficiency and in Anephric Patients

J. Verheijen, D. Rijken, E. Brommer, 1984, Thrombosis and Haemostasis.

Fibrinolytic Properties of Single Chain Urokinase-type Plasminogen Activator (Pro-urokinase)

D. Rijken, G. Munk, 1990 .

The Amount of Plasminogen, Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 in Human Thrombi and the Relation to IVVO-TNO Lysibility

D. Rijken, E. Brommer, B. Potter van Loon, 1992, Thrombosis and Haemostasis.

On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction.

J. Jespersen, C. Kluft, J. Gram, 2009, Acta medica Scandinavica.

Masking of Fibrinolytic Response to Stimulation by an Inhibitor of Tissue-Type Plasminogen Activator in Plasma

J. Verheijen, D. Rijken, E. Brommer, 1984, Thrombosis and Haemostasis.

Fibrinolytic shut‐down after surgery: impairment of the balance between tissue‐type plasminogen activator and its specific inhibitor

P. Mannucci, J. Verheijen, C. Kluft, 1985, European journal of clinical investigation.

PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) ANTIGEN LEVELS IN HUMAN PLASMA SAMPLES

D. Rijken, E. Sprengers, L. Engesser, 1988 .

a 2-Antiplasmin Enschede : Dysfunctional a 2-Antiplasmin Molecule Associated with an Autosomal Recessive Hemorrhagic Disorder

J., G. Dooijewaard, C. Kluft, 2013 .

Autosomal Recessive Hemorrhagic Disorder

G. Dooijewaard, C. Kluft, D. Rijken, 2022 .

Plasminogen Activation at Low Temperatures in Plasma Samples Gontaining Therapeutic Concentrations of Tissue-Type Plasm i nogen Activator or Other Thrombolytic Agents

E. Seifried, G. Dooijewaard, D. Rijken, 1990, Thrombosis and Haemostasis.

High functional levels of thrombin‐activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke

F. Leebeek, D. Rijken, D. Dippel, 2005, Journal of thrombosis and haemostasis : JTH.

A new functional assay of thrombin activatable fibrinolysis inhibitor

R. Bertina, D. Rijken, A. H. C. Guimarães, 2005, Journal of thrombosis and haemostasis : JTH.

alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.

G. Dooijewaard, C. Kluft, D. Rijken, 1987, Journal of Clinical Investigation.

Migration of the activation peptide of thrombin‐activatable fibrinolysis inhibitor (TAFI) during SDS–polyacrylamide gel electrophoresis

A. Gils, P. Declerck, D. Rijken, 2004, Journal of thrombosis and haemostasis : JTH.

Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.

M. Levi, F. Haverkate, M. D. de Maat, 1999, The Journal of laboratory and clinical medicine.

Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

A. Gils, J. Hazelzet, P. Declerck, 2008, Journal of thrombosis and haemostasis : JTH.

Fibrinolytic properties of activated FXII.

G. Dooijewaard, D. Rijken, E. Braat, 1999, European journal of biochemistry.

Mechanisms of plasminogen activation

V. Ellis, H. Pannekoek, D. Collen, 1994, Journal of internal medicine.

Daytime Fluctuations in Blood of Tissue-Type Plasminogen Activator (t-PA) and Its Fast-Acting Inhibitor (PAI-1)

J. Verheijen, C. Kluft, D. Rijken, 1988, Thrombosis and Haemostasis.

Fibrinolytic properties of activated factor XII

G. Dooijewaard, D. Rijken, B. Eam, 1998 .

Interaction of Plasminogen Activators and Plasminogen with Heparin: Effect of Ionic Strength

D. Rijken, D. Rijken, A. Jie, 1993, Thrombosis and Haemostasis.

Increased Plasminogen Activator Inhibition Levels in Malignancy

J. T. ten Cate, G. Dooijewaard, D. Rijken, 1987, Thrombosis and Haemostasis.

Urokinase-mediated fibrinolysis in the synovial fluid of rheumatoid arthritis patients may be affected by the inactivation of single chain urokinase type plasminogen activator by thrombin

H. Ronday, D. Rijken, B. Beekman, 2000, Annals of the rheumatic diseases.

Binding and retention of polycationic peptides and dendrimers in the vascular wall

D. Filippov, D. Rijken, D. V. Sakharov, 2003, FEBS letters.

FIBRIN DEGRADATION PRODUCTS ARE NOT SPECIFIC MARKERS FOR THROMBOLYSIS IN MYOCARDIAL INFARCTION

E. Seifried, W. Nieuwenhuizen, C. Kluft, 1987, The Lancet.

Composition and Susceptibility to Thrombolysis of Pathological Human Arterial Thrombi

D. Rijken, E. Brommer, J. H. Bockel, 1992, Annals of the New York Academy of Sciences.

In Vitro Stability of a Tissue-Type Plasminogen Activator Mutant, BM 06.022, in Human Plasma

D. Rijken, D. Rijken, M. Barrett-Bergshoeff, 1994, Thrombosis and Haemostasis.

PRODUCTION BY HUMAN TISSUES IN CULTURE OF IMMUNOLOGICALLY DISTINCT, MULTIPLE MOLECULAR WEIGHT FORMS OF PLASMINOGEN ACTIVATORS *

D. Rijken, D. Rijken, G. Wijngaards, 1981, Annals of the New York Academy of Sciences.